Radar · Life Sciences in United States
Best Life Sciences Companies in United States
The 19639 best Life Sciences companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Moderna.
By Riya SenguptaFinancials
19639companies tracked
$396.2Bdisclosed funding
47unicorns
9286have raised
$396.2 billion in disclosed funding across 19,639 tracked companies tells you exactly how seriously the United States treats Life Sciences as an economic engine. This directory ranks the best Life Sciences companies operating in the United States by disclosed equity funding and recent funding momentum, and the numbers make a compelling case for why this sector commands attention from institutional capital at scale.
Verily leads with $2.5B raised, and GRAIL follows at $2.0B, two data points that illustrate how outsized the top of this market really is. The global life sciences market was pegged at roughly $167.8B back in 2004 and has compounded at approximately 10.2% annually since, driven by an aging population, strong job growth, and sustained institutional funding. I'd also note that mobile engagement is validating the sector's reach: median install growth across life and health sciences apps hit roughly +43% YoY across 15 tracked apps. So when you're evaluating which companies here deserve your attention, look past the headline rounds. HHS, NIH, and RA Capital Management anchor the investor side, meaning the most active backers here aren't chasing hype. They're writing checks into companies with 47 unicorns already minted from this pool. That's the floor, not the ceiling.
Sources & further reading
- Uncover vital clues how police officers find fingerprints on paper
- Promising Biotech Stocks To Watch Now – April 2nd
- Delivering higher output at lower costs
FLIAR INTELLIGENCE · LIFE SCIENCES × UNITED STATES
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
1.5Mcombined LinkedIn audience
56%of audience held by top 3
6companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Verily 🦄 A data platform and technology company purpose-built to power AI-enabled precision health 84News top 13%Funding top 14%Talent top 22%Growth top 25% All 12 signals ▾Newstop 13% Fundingtop 14% Talenttop 22% Growthtop 25% Moattop 26% Techtop 30% Markettop 31% Producttop 32% Customerstop 34% Partnerstop 41% Innovationtop 42% Globaltop 48% News: 7 BI events in 12 mo (of 67 tracked, 9 types) · +600% YoY Funding: Raised $2.5B across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 84/100 | $2.5B | 3 mo ago | 1,564 | Andrew Conrad Co-Founder | Apple iCloud MailGoogle WorkspaceNode.js+24 | 7 signals ▲600% Funding · New product · Layoffs | — | — |
| 2 | GRAIL Developer of a screening platform for circulating tumor DNA to detect cancer 78Patents top 13%Tech top 16%News top 17%Funding top 20% All 12 signals ▾Patentstop 13% Techtop 16% Newstop 17% Fundingtop 20% Innovationtop 25% Growthtop 36% Markettop 37% Moattop 38% Partnerstop 40% Globaltop 49% Fin. healthbottom 49% Talentbottom 49% Patents: 899 patents matched (strict assignee match) · 523 filings since 2022 vs 371 in 2017-21 Tech: 51 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront rank vs industry peers · Fliar Intelligence Index 78/100 | $2.0B | 7 mo ago | 491 491 → 1,111 (+126%) · sector median +34% | Bob Ragusa Chief Executive Officer | WordPressApple iCloud MailGoogle Workspace+24 | 11 signals ▲83% Funding · Announcements · Earnings | 899 patents Liquid biopsy cancer detection via cfDNA methylation and fragment analysis | — |
| 3 | Earendil Provider of AI-driven technology platforms that enable the discovery and development of protein therapeutics 45Funding top 12%AI top 35%Talent top 38%Patents top 46% All 8 signals ▾Fundingtop 12% AItop 35% Talenttop 38% Patentstop 46% Innovationtop 50% Globaltop 50% Techbottom 36% Marketbottom 25% Funding: Raised $787M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: ai-driven, deep learning rank vs industry peers · Fliar Intelligence Index 45/100 | $787M | 2 mo ago | — | Zhenping Zhu Co-Founder & Co-CEO | GoDaddy Website BuilderReactRequireJS+8 | — | 6 patents Therapeutic antibodies, especially bispecific and anti‑TL1A biologics for immune modulation | — |
| 4 | XtalPi 🦄 AI-based drug research and development company 64Funding top 18%AI top 26%Talent top 28%Patents top 31% All 13 signals ▾Fundingtop 18% AItop 26% Talenttop 28% Patentstop 31% Moattop 31% Innovationtop 34% Producttop 35% Newstop 38% Techtop 39% Growthtop 47% Globaltop 50% Marketbottom 43% Fin. healthbottom 32% Funding: Raised $785M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) AI: Classified as an AI company · Product described with: ai-based, machine learning rank vs industry peers · Fliar Intelligence Index 64/100 | $785M | 9 mo ago | 27 | — | WordPressMySQLPHP+28 | 4 signals Earnings | 14 patents Small-molecule STING agonists and PI3Kβ inhibitors for immuno‑oncology therapeutics | 1 partnership |
| 5 | Summit Developer of therapeutics for oncology and rare diseases 22Partners top 31%Funding top 33%Product top 35%News top 37% All 13 signals ▾Partnerstop 31% Fundingtop 33% Producttop 35% Newstop 37% Techtop 45% Growthbottom 43% Moatbottom 43% Marketbottom 42% Talentbottom 41% Globalbottom 37% Patentsbottom 30% Innovationbottom 26% Fin. healthbottom 22% Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $713M | 7 mo ago | 99 | Maky Zanganeh CEO | WordPress Block EditorWordPressMySQL+18 | 11 signals ▼45% M&A · Contracts · Acquisition | 13 patents Digital media submission, processing, and distribution platforms for online content management. | — |
| 6 | Neuralink 🦄 Provider of implantable brain-computer interfaces 78Funding top 15%Patents top 25%Moat top 25%Innovation top 27% All 10 signals ▾Fundingtop 15% Patentstop 25% Moattop 25% Innovationtop 27% Talenttop 28% Markettop 33% Growthtop 42% Techtop 44% Globalbottom 39% Newsbottom 24% Funding: Raised $680M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) Patents: 97 patents matched (strict assignee match) · 62 filings since 2022 vs 35 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $680M | 1 mo ago | 197 | Dongjin Seo Co-Founder | Apple iCloud MailGoogle WorkspaceGSAP+12 | — | 97 patents High‑density, biocompatible neural interface hardware and real‑time spike processing | 1 launch |
| 7 | Immunic Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases 35Funding top 19%Tech top 41%Moat top 48%Growth top 50% All 9 signals ▾Fundingtop 19% Techtop 41% Moattop 48% Growthtop 50% Talentbottom 49% Globalbottom 45% Newsbottom 40% Marketbottom 38% Fin. healthbottom 20% Funding: Raised $560M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) Tech: 34 technologies across 3/8 capability areas · Cloud: Cloudflare, Google Cloud rank vs industry peers · Fliar Intelligence Index 35/100 | $560M | 4 mo ago | 77 77 → 91 (+18%) · sector median +34% | Daniel Vitt Chief Executive Officer | Froala EditorPHPHighcharts+18 | 3 signals ▼77% Funding | — | — |
| 8 | Guardant Health Developer of digital sequencing technology for cancer detection 90Patents top 14%Funding top 15%Innovation top 17%Moat top 19% All 13 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Moattop 19% Markettop 23% Techtop 23% Newstop 29% Growthtop 30% Producttop 35% Fin. healthtop 36% Partnerstop 41% Globaltop 45% Talenttop 46% Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 90/100 | $557M | 7 mo ago | 1,351 | Amirali Talasaz Co-founder and Co-Chief Executive Officer | WordPressBugHerdApple iCloud Mail+25 | 25 signals ▲56% Earnings · Announcements · Regulatory | 996 patents Liquid biopsy cfDNA sequencing and analysis for cancer detection and monitoring | 1 launch · 1 partnership |
| 9 | Imperative Care Provider of access catheters for cardiovascular diagnosis and treatment 82Funding top 14%Patents top 15%Innovation top 18%Moat top 26% All 10 signals ▾Fundingtop 14% Patentstop 15% Innovationtop 18% Moattop 26% Growthtop 27% Techtop 36% Talenttop 38% Markettop 48% Newsbottom 48% Globalbottom 42% Funding: Raised $496M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Patents: 261 patents matched (strict assignee match) · 225 filings since 2022 vs 36 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $496M | 3 mo ago | 90 | Dr Hopkins Co-founder | WordPressApple iCloud MailMicrosoft 365+27 | 4 signals ▼33% Funding | 261 patents Robotic-assisted neurovascular catheter systems for precise multi‑catheter interventions | — |
| 10 | Mirador Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases 50Funding top 15%Growth top 35%Moat top 42%Tech top 44% All 9 signals ▾Fundingtop 15% Growthtop 35% Moattop 42% Techtop 44% Producttop 49% Talentbottom 49% Newsbottom 38% Globalbottom 36% Marketbottom 32% Funding: Raised $480M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $480M | 5 mo ago | — | Mark McKenna Founder & CEO | WordPressApple iCloud MailMicrosoft 365+21 | — | — | — |
| 11 | Vor Biopharma Developer of therapeutics to treat acute myeloid leukemia 78Funding top 12%Patents top 19%Innovation top 20%News top 24% All 10 signals ▾Fundingtop 12% Patentstop 19% Innovationtop 20% Newstop 24% Talenttop 27% Moattop 35% Growthtop 39% Techtop 40% Markettop 47% Globalbottom 40% Funding: Raised $477M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Patents: 188 patents matched (strict assignee match) · 154 filings since 2022 vs 34 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $477M | 6 mo ago | 133 | Siddhartha Mukherjee Founder | WordPressApple iCloud MailMySQL+29 | 29 signals ▲262% Leadership · Earnings · Funding | 188 patents Patents concentrated in health & consumer products | — |
| 12 | Impulse Dynamics Provider of implantable device for treatment of chronic heart failure 40Funding top 13%Moat top 31%Product top 34%Tech top 49% All 10 signals ▾Fundingtop 13% Moattop 31% Producttop 34% Techtop 49% Patentsbottom 49% Globalbottom 46% Innovationbottom 45% Marketbottom 41% Growthbottom 38% Newsbottom 27% Funding: Raised $443M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 18 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $443M | 6 mo ago | 36 | — | WordPressMySQLPHP+24 | — | 18 patents Implantable cardiac muscle stimulation devices and protein‑based therapeutic modulation. | — |
| 13 | Quince Therapeutics Developer of therapeutics for orthopedic diseases 53Funding top 13%Growth top 37%Tech top 44%Moat top 48% All 8 signals ▾Fundingtop 13% Growthtop 37% Techtop 44% Moattop 48% Talentbottom 49% Marketbottom 37% Newsbottom 37% Globalbottom 37% Funding: Raised $420M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $420M | 1 mo ago | 21 | Dirk Thye CEO | DrupalPHPZURB Foundation+20 | — | — | — |
| 14 | Century Therapeutics Developer of therapeutics for the treatment of autoimmune diseases and cancer 72Funding top 17%Growth top 30%Fin. health top 34%Market top 40% All 8 signals ▾Fundingtop 17% Growthtop 30% Fin. healthtop 34% Markettop 40% Moattop 42% Techbottom 45% Globalbottom 39% Newsbottom 23% Funding: Raised $410M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Growth: Revenue +1557% YoY · 1 acquisition/expansion move in 24 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $410M | 5 mo ago | 94 94 → 118 (+26%) · sector median +34% | — | DrupalPHPAmazon Web Services+20 | — | — | 1 award |
| 15 | Lexicon Pharmaceuticals Developer of small molecule drugs for diffrent health diseases 76Funding top 20%Patents top 24%Talent top 28%Growth top 30% All 11 signals ▾Fundingtop 20% Patentstop 24% Talenttop 28% Growthtop 30% Techtop 35% Innovationtop 40% Markettop 41% Fin. healthtop 41% Moattop 44% Newstop 45% Globalbottom 44% Funding: Raised $381M across 9 rounds · 9 rounds over 28 yrs (0.3/yr) Patents: 1,211 patents matched (strict assignee match) · 94 filings since 2022 vs 219 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $381M | 4 mo ago | 135 135 → 284 (+110%) · sector median +34% | Ivan Cheung Board of Directors | DrupalApple iCloud MailPHP+31 | 15 signals ▼35% Announcements · Capital raise · Acquisition | 1,211 patents Patents concentrated in chemistry & materials | — |
| 16 | Science 🦄 Provider of online science magazine 72Funding top 13%Patents top 20%Moat top 24%Innovation top 33% All 9 signals ▾Fundingtop 13% Patentstop 20% Moattop 24% Innovationtop 33% Growthtop 35% Markettop 38% Globaltop 42% Talentbottom 49% Techbottom 46% Funding: Raised $360M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Patents: 245 patents matched (strict assignee match) · 102 filings since 2022 vs 115 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $360M | 3 mo ago | 76 | Max Hodak Founder & CEO | Apple iCloud MailGoogle WorkspaceRuby+12 | — | 245 patents Specialty surfactants and polyether polymer derivatives for cosmetics and advanced chemical synthesis | 3 job openings · 1 award |
| 17 | Cellares Manufacturer of a medical device for cell-based therapy 82Funding top 15%News top 19%Innovation top 23%Growth top 25% All 11 signals ▾Fundingtop 15% Newstop 19% Innovationtop 23% Growthtop 25% Patentstop 27% Moattop 28% Partnerstop 31% Talenttop 35% Markettop 41% Techtop 43% Globalbottom 39% Funding: Raised $355M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 9 BI events in 12 mo (of 25 tracked, 4 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 82/100 | $355M | 4 mo ago | 154 | Fabian Gerlinghaus Co-Founder & CEO | WordPressApple iCloud MailGoogle Workspace+32 | 9 signals ▲200% Leadership · Contracts · Funding | 89 patents Patents concentrated in transport & manufacturing processes | 1 partnership · 1 expansion · 1 award |
| 18 | Enable Injections Provider of a wearable drug delivery solution 76Funding top 17%Patents top 23%Innovation top 26%Growth top 26% All 10 signals ▾Fundingtop 17% Patentstop 23% Innovationtop 26% Growthtop 26% Moattop 26% Techtop 42% Markettop 46% Talentbottom 49% Globalbottom 44% Newsbottom 27% Funding: Raised $304M across 10 rounds · 10 rounds over 15 yrs (0.7/yr) Patents: 219 patents matched (strict assignee match) · 109 filings since 2022 vs 93 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $304M | 5 mo ago | 166 166 → 223 (+34%) · sector median +34% | Mike Hooven Founder & CEO | WordPressMySQLPHP+24 | — | 219 patents Handheld injection and fluid transfer devices with safety locking and site monitoring | — |
| 19 | Celularity Developer of allogeneic cell therapies to treat multiple diseases 67Funding top 18%Patents top 30%Fin. health top 38%Moat top 38% All 11 signals ▾Fundingtop 18% Patentstop 30% Fin. healthtop 38% Moattop 38% Innovationtop 39% Growthtop 39% Newstop 39% Markettop 40% Techtop 48% Talentbottom 49% Globalbottom 40% Funding: Raised $290M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) Patents: 488 patents matched (strict assignee match) · 135 filings since 2022 vs 309 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $290M | 5 mo ago | 225 225 → 145 (-36%) · sector median +34% | Robert Hariri Chairman & CEO | WordPressMySQLPHP+22 | 8 signals ▼38% Earnings · Funding · Announcements | 488 patents Placental-derived extracellular matrix and engineered immune cell therapies for regenerative medicine | — |
| 20 | Evommune Developer of therapeutic options for chronic inflammatory disorders 60Growth top 16%Funding top 18%News top 25%Tech top 47% All 10 signals ▾Growthtop 16% Fundingtop 18% Newstop 25% Techtop 47% Fin. healthtop 47% Moattop 47% Patentsbottom 47% Marketbottom 46% Innovationbottom 42% Globalbottom 39% Growth: Revenue +86% YoY · Fresh capital in last 24 mo Funding: Raised $268M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $268M | 4 mo ago | 33 | — | WordPressMySQLPHP+20 | 15 signals ▲650% IPO · Earnings · M&A | 3 patents Small-molecule PKCθ inhibitors for immune‑modulating therapeutics | 2 launchs · 1 partnership |
| 21 | Achieve Life Sciences Developer of plant-based alkaloid for treating smoking cessation 37Funding top 11%News top 42%Moat top 48%Tech top 50% All 7 signals ▾Fundingtop 11% Newstop 42% Moattop 48% Techtop 50% Globalbottom 44% Marketbottom 40% Growthbottom 34% Funding: Raised $264M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) News: 9 BI events in 12 mo (of 54 tracked, 8 types) · -53% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $264M | 1 mo ago | 25 25 → 40 (+60%) · sector median +34% | — | WordPress Block EditorWordPressMySQL+17 | 9 signals ▼53% Leadership · Earnings | — | — |
| 22 | Terremoto Developer of small-molecule therapeutics for cancer treatment 60Funding top 15%Talent top 28%Moat top 31%Growth top 35% All 7 signals ▾Fundingtop 15% Talenttop 28% Moattop 31% Growthtop 35% Techtop 49% Marketbottom 41% Globalbottom 36% Funding: Raised $250M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 60/100 | $250M | 2 mo ago | 35 | Matt Jacobson Co-Founder | WordPressBugHerdZendesk+24 | — | — | — |
| 23 | CytoDyn Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection 32Funding top 17%Growth top 35%Patents top 36%Innovation top 44% All 10 signals ▾Fundingtop 17% Growthtop 35% Patentstop 36% Innovationtop 44% Moatbottom 49% Globalbottom 36% Techbottom 35% Newsbottom 26% Marketbottom 25% Fin. healthbottom 24% Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $250M | 3 mo ago | 12 12 → 23 (+92%) · sector median +34% | — | Apple iCloud MailMicrosoft 365Bootstrap+8 | — | 107 patents CCR5-targeted biologics for HIV, cancer, NAFLD/NASH and immune‑modulating therapies | 1 partnership |
| 24 | Cognito Therapeutics Developer of a medical device for the treatment of Alzheimer's disease 60Talent top 22%Funding top 23%Growth top 35%Moat top 42% All 8 signals ▾Talenttop 22% Fundingtop 23% Growthtop 35% Moattop 42% Techtop 50% Marketbottom 43% Globalbottom 37% Newsbottom 21% Talent: Analyst team rating 5/5 · 3 named leaders on record Funding: Raised $227M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $227M | 3 mo ago | 42 | Ed Boyden Co-Founder | WebflowGSAPUnpkg+12 | — | — | — |
| 25 | NovaBay Pharmaceuticals Developer of eye care and wound care products 32Funding top 21%Product top 35%News top 46%Talent bottom 49% All 10 signals ▾Fundingtop 21% Producttop 35% Newstop 46% Talentbottom 49% Moatbottom 44% Marketbottom 43% Techbottom 41% Growthbottom 40% Globalbottom 38% Fin. healthbottom 37% Funding: Raised $220M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) Product: 0 product launch events in 12 mo · Company stage: Public rank vs industry peers · Fliar Intelligence Index 32/100 | $220M | 5 mo ago | 33 33 → 38 (+15%) · sector median +34% | Justin Hall CEO | WordPressApple iCloud MailMicrosoft 365+20 | 5 signals ▼62% M&A · Regulatory · Announcements | — | — |
| 26 | Apnimed Developer of small molecule based therapeutics for the treatment of obstructive sleep apnea 37Funding top 14%Growth top 28%Talent top 28%Moat top 35% All 12 signals ▾Fundingtop 14% Growthtop 28% Talenttop 28% Moattop 35% Producttop 40% Techbottom 49% Globalbottom 37% Patentsbottom 34% Marketbottom 32% Innovationbottom 21% Newsbottom 18% Customersbottom 3% Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $208M | 2 mo ago | 13 | Andrew Wellman Co-Founder | WordPressApple iCloud MailMySQL+21 | — | 2 patents Pharmaceutical solid‑form optimization and repurposed drug therapy for sleep‑apnea treatment | 1 job opening · 1 award |
| 27 | Iambic Therapeutics Provider of AI-driven drug discovery platform for the treatment of cancer 60Funding top 15%AI top 26%Moat top 31%Talent top 38% All 9 signals ▾Fundingtop 15% AItop 26% Moattop 31% Talenttop 38% Growthtop 45% Marketbottom 43% Newsbottom 43% Techbottom 40% Globalbottom 39% Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) AI: Classified as an AI company · Product described with: ai driven, ai-driven rank vs industry peers · Fliar Intelligence Index 60/100 | $206M | 2 mo ago | 50 | Fred Manby Co-Founder & CTO | WebflowApple iCloud MailMicrosoft 365+13 | — | — | — |
| 28 | Candid Therapeutics Developer of therapeutics for autoimmune diseases 40Funding top 17%Growth top 38%News top 48%Moat top 48% All 8 signals ▾Fundingtop 17% Growthtop 38% Newstop 48% Moattop 48% Talentbottom 49% Techbottom 38% Globalbottom 38% Marketbottom 32% Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $206M | 3 mo ago | — | Ken Song CEO | WordPressMySQLPHP+15 | 4 signals M&A | — | — |
| 29 | Nuvaira Provider of a catheter-based system for patients suffering from COPD 57Funding top 18%Moat top 23%Product top 31%Patents top 33% All 11 signals ▾Fundingtop 18% Moattop 23% Producttop 31% Patentstop 33% Innovationtop 35% Growthtop 40% Talentbottom 49% Marketbottom 46% Techbottom 46% Globalbottom 40% Newsbottom 27% Funding: Raised $191M across 10 rounds · 10 rounds over 17 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $191M | 3 mo ago | 57 | Dennis Wahr CEO | WordPress Block EditorWordPressApple iCloud Mail+18 | — | 97 patents Minimally invasive therapeutic devices for respiratory, esophageal and catheter-based interventions | 1 job opening |
| 30 | Bioventrix Ventricle reshaping device 40Funding top 16%Moat top 19%Patents top 36%Talent top 38% All 9 signals ▾Fundingtop 16% Moattop 19% Patentstop 36% Talenttop 38% Innovationtop 43% Globalbottom 45% Techbottom 36% Marketbottom 30% Newsbottom 27% Funding: Raised $181M across 25 rounds · 25 rounds over 22 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 185 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $181M | 2 mo ago | 20 20 → 23 (+15%) · sector median +34% | Lon Annest Co-Founder | WordPressMySQLPHP+17 | — | 185 patents Percutaneous cardiac implant and monitoring systems for heart failure treatment | — |
| 31 | Monteris Minimally invasive robotic laser thermotherapy 55Funding top 15%Moat top 31%Talent top 38%Market top 43% All 8 signals ▾Fundingtop 15% Moattop 31% Talenttop 38% Markettop 43% Growthtop 48% Newsbottom 42% Techbottom 38% Globalbottom 37% Funding: Raised $174M across 20 rounds · 20 rounds over 18 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $174M | 3 mo ago | 100 100 → 128 (+28%) · sector median +34% | Richard Tyc Co-Founder & SVP Science & Technology | — | — | — | — |
| 32 | Senti Bio Developer of cell and gene therapies for patients living with incurable diseases 45Product top 14%Funding top 21%Talent top 22%Tech top 32% All 11 signals ▾Producttop 14% Fundingtop 21% Talenttop 22% Techtop 32% Innovationtop 34% Newsbottom 43% Moatbottom 43% Growthbottom 39% Globalbottom 39% Marketbottom 32% Fin. healthbottom 20% Product: 4 distinct product lines · Company stage: Public Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $158M | 1 mo ago | 122 | Jim Collins Co-Founder | DrupalPHPSalesforce+24 | 3 signals ▼75% Earnings · Announcements | — | — |
| 33 | Cala Health Developer of a wearable non-invasive neuromodulation device 60Funding top 17%Product top 21%Innovation top 22%Patents top 26% All 11 signals ▾Fundingtop 17% Producttop 21% Innovationtop 22% Patentstop 26% Moattop 26% Talenttop 38% Techtop 46% Growthbottom 44% Marketbottom 43% Globalbottom 42% Newsbottom 21% Funding: Raised $157M across 7 rounds · 7 rounds over 13 yrs (0.5/yr) Product: 6 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 60/100 | $157M | 1 mo ago | 50 50 → 122 (+144%) · sector median +34% | Kate Rosenbluth Founder and Co-President | WordPressApple iCloud MailGoogle Workspace+31 | — | 243 patents Wearable peripheral nerve stimulation devices for tremor, movement and musculoskeletal disorder therapy | 1 award |
| 34 | Casma Therapeutics Developer of therapies for treating rare genetic disorders 40Funding top 20%Product top 30%Innovation top 38%Moat top 48% All 9 signals ▾Fundingtop 20% Producttop 30% Innovationtop 38% Moattop 48% Marketbottom 48% Growthbottom 41% Globalbottom 37% Newsbottom 22% Techbottom 21% Funding: Raised $154M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Product: 3 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 40/100 | $154M | 3 mo ago | 38 | — | — | — | — | — |
| 35 | Life Biosciences Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases 53Funding top 16%Growth top 28%Moat top 31%News top 43% All 7 signals ▾Fundingtop 16% Growthtop 28% Moattop 31% Newstop 43% Techtop 49% Globalbottom 39% Marketbottom 33% Funding: Raised $150M across 9 rounds · 9 rounds over 8 yrs (1.1/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $150M | 2 mo ago | 14 14 → 27 (+93%) · sector median +34% | — | WordPressMySQLPHP+20 | — | — | — |
| 36 | Alto Neuroscience AI-driven drug discovery platform for neurological diseases based on patients biomarkers 72Funding top 12%Patents top 25%Growth top 30%Moat top 32% All 11 signals ▾Fundingtop 12% Patentstop 25% Growthtop 30% Moattop 32% Innovationtop 33% Techtop 45% AItop 45% Globalbottom 49% Talentbottom 49% Newsbottom 44% Marketbottom 40% Funding: Raised $145M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Patents: 57 patents matched (strict assignee match) · 57 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $145M | 3 mo ago | 34 | Amit Etkin Founder & CEO | BugHerdApple iCloud MailGoogle Workspace+15 | 3 signals ▼25% Earnings | 57 patents Neuropsychiatric therapeutics: combinatorial dopaminergic/serotonergic drugs and EEG‑guided patient selection | 1 award |
| 37 | Endogenex Developer of medical devices for the treatment of Type 2 diabetes 37Funding top 18%Innovation top 39%Moat top 39%Patents top 41% All 9 signals ▾Fundingtop 18% Innovationtop 39% Moattop 39% Patentstop 41% Talentbottom 49% Globalbottom 37% Techbottom 35% Marketbottom 31% Newsbottom 20% Funding: Raised $140M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Innovation: 25 patents (top 67% of patent-holders) · 24 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $140M | 2 mo ago | 15 15 → 27 (+80%) · sector median +34% | Michael Brenzel Co-Founder & CTO | WordPress Block EditorWordPressMySQL+16 | — | 25 patents Pulsed electric field electroporation devices for tissue ablation, especially gastrointestinal applications. | 1 launch |
| 38 | Harbinger Health AI-based cancer detection tool for providers 55Funding top 18%News top 36%Moat top 42%AI top 45% All 8 signals ▾Fundingtop 18% Newstop 36% Moattop 42% AItop 45% Talenttop 49% Techbottom 48% Marketbottom 43% Globalbottom 38% Funding: Raised $140M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) News: 2 BI events in 12 mo (of 13 tracked, 3 types) · Top themes: Leadership rank vs industry peers · Fliar Intelligence Index 55/100 | $140M | 2 mo ago | 60 | Stephen Hahn CEO | WordPressApple iCloud MailMySQL+23 | — | — | 2 launchs |
| 39 | Precision BioSciences Developer of gene editing therapies to treat rare genetic diseases 57Product top 19%Funding top 21%Moat top 32%Patents top 36% All 11 signals ▾Producttop 19% Fundingtop 21% Moattop 32% Patentstop 36% Newstop 38% Markettop 39% Techtop 41% Innovationtop 42% Growthbottom 47% Globalbottom 42% Fin. healthbottom 39% Product: 3 distinct product lines · Company stage: Public Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $136M | 3 mo ago | 236 | — | DrupalApple iCloud MailMicrosoft 365+23 | 3 signals ▲50% Regulatory · Earnings · Capital raise | 68 patents Therapeutic genome editing using engineered meganucleases and engineered T‑cell therapies | 1 launch |
| 40 | Lifeward Developer of exoskeletons for individuals with spinal cord injuries and stroke rehabilitation 50Funding top 22%Product top 28%News top 30%Partners top 31% All 13 signals ▾Fundingtop 22% Producttop 28% Newstop 30% Partnerstop 31% Techtop 40% Growthtop 47% Moattop 47% Markettop 48% Patentstop 50% Talentbottom 49% Innovationbottom 48% Fin. healthbottom 40% Globalbottom 39% Funding: Raised $132M across 13 rounds · 13 rounds over 15 yrs (0.9/yr) Product: 1 published app (39 installs) · Company stage: Public rank vs industry peers · Fliar Intelligence Index 50/100 | $132M | 2 mo ago | — | Larry Jasinski CEO & MD | WordPressMySQLPHP+31 | 10 signals Earnings · Contracts · M&A | 3 patents Pressure‑based anti‑gravity exercise and rehabilitation equipment for user weight support | 1 launch |
| 41 | Endovascular Engineering Provider of mechanical thrombectomy technologies to treat venous thromboembolism 48Funding top 18%Growth top 30%Talent top 38%News top 47% All 8 signals ▾Fundingtop 18% Growthtop 30% Talenttop 38% Newstop 47% Moatbottom 48% Globalbottom 38% Marketbottom 36% Techbottom 30% Funding: Raised $122M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $122M | 2 mo ago | 19 | Mike Rosenthal Co-Founder & Chief Operating Officer | WordPressApple iCloud MailMicrosoft 365+17 | 3 signals ▲50% Funding | — | 3 job openings · 1 internship |
| 42 | CREATE Medicines Developer of messenger ribonucleic acid therapies for immune cell programming 50Funding top 20%Patents top 41%Innovation top 47%Talent bottom 49% All 5 signals ▾Fundingtop 20% Patentstop 41% Innovationtop 47% Talentbottom 49% Globalbottom 35% Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $122M | 1 mo ago | — | Daniel Getts Co-Founder & CEO | — | — | 18 patents Therapeutic chimeric fusion proteins and gene/miRNA delivery platforms for drug development | — |
| 43 | Adela Developer of a platform for detection of cancer 57Funding top 22%Moat top 31%Patents top 38%Talent top 38% All 8 signals ▾Fundingtop 22% Moattop 31% Patentstop 38% Talenttop 38% Markettop 46% Innovationtop 49% Globalbottom 40% Newsbottom 22% Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $109M | 2 mo ago | 62 | Manish Agarwal Co-Founder | — | — | 15 patents Liquid biopsy nucleic acid extraction and sequencing library preparation technologies | 1 job opening · 1 partnership |
| 44 | Ray Therapeutics Developer of therapeutics for degenerative retinal diseases 48Funding top 19%Growth top 35%Tech top 40%Moat top 42% All 7 signals ▾Fundingtop 19% Growthtop 35% Techtop 40% Moattop 42% Talentbottom 49% Globalbottom 39% Marketbottom 28% Funding: Raised $106M across 6 rounds · 6 rounds over 4 yrs (1.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $106M | 1 mo ago | 10 | Paul Bresge Co-Founder & CEO | WordPressMySQLMariaDB+21 | — | — | — |
| 45 | Karyopharm Biopharmaceutical company focused on developing and commercializing innovative cancer therapies 69Funding top 17%News top 26%Market top 32%Tech top 34% All 9 signals ▾Fundingtop 17% Newstop 26% Markettop 32% Techtop 34% Moattop 42% Fin. healthtop 43% Talenttop 45% Growthbottom 49% Globalbottom 49% Funding: Raised $98.4M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) News: 30 BI events in 12 mo (of 119 tracked, 8 types) · +114% YoY rank vs industry peers · Fliar Intelligence Index 69/100 | $98M | 2 mo ago | 325 325 → 320 (-2%) · sector median +34% | Michael Kauffman Cofounder | WordPressApple iCloud MailMySQL+27 | 30 signals ▲114% Announcements · Earnings · Funding | — | — |
| 46 | AcuityMD Platform offering CRM software to the medical industry 53Funding top 18%News top 25%Talent top 28%Growth top 35% All 10 signals ▾Fundingtop 18% Newstop 25% Talenttop 28% Growthtop 35% Producttop 36% Moattop 39% Techtop 48% Marketbottom 42% Innovationbottom 37% Globalbottom 34% Funding: Raised $83.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 4 BI events in 12 mo (of 11 tracked, 3 types) · Top themes: Funding, New product rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | 48 | Michael Monovoukas Co-Founder & CEO | WebflowApple iCloud MailGoogle Workspace+20 | 4 signals Funding · New product | — | — |
| 47 | Cresilon Developer of hemostatic products for wound care 60Funding top 22%Growth top 32%Moat top 32%Product top 35% All 10 signals ▾Fundingtop 22% Growthtop 32% Moattop 32% Producttop 35% Techtop 37% Patentstop 42% Innovationtop 48% Marketbottom 46% Globalbottom 36% Newsbottom 18% Funding: Raised $81.7M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Growth: Headcount 53 → 73 (+38%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $82M | 1 mo ago | 73 | — | WordPressApple iCloud MailMicrosoft 365+36 | — | 40 patents Hemostatic polymer adhesives and delivery devices for rapid surgical bleeding control | — |
| 48 | Miach Orthopaedics Developer of surgical implants for connective tissue repair 64Funding top 23%Talent top 28%Patents top 32%Moat top 32% All 10 signals ▾Fundingtop 23% Talenttop 28% Patentstop 32% Moattop 32% Growthtop 35% Innovationtop 39% Techtop 48% Marketbottom 46% Globalbottom 42% Newsbottom 22% Funding: Raised $72.5M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) Talent: Analyst team rating 5/5 · 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 64/100 | $72M | 1 mo ago | 46 | Martha Murray Founder | WordPressMySQLPHP+21 | — | 33 patents Injectable collagen biomaterials for orthopedic tissue repair and regeneration | — |
| 49 | ClearNote Health Developer of non-invasive cancer detection methods 40Moat top 22%Funding top 36%Market top 50%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 36% Markettop 50% Talentbottom 49% Globalbottom 36% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $70M | 0 mo ago | 45 | Dave Mullarkey Chief Executive Officer | — | — | — | — |
| 50 | Cagent Vascular Developer of a device for removal of vascular blockages 57Moat top 21%Funding top 24%Patents top 30%Innovation top 31% All 9 signals ▾Moattop 21% Fundingtop 24% Patentstop 30% Innovationtop 31% Techtop 34% Talentbottom 49% Globalbottom 45% Marketbottom 39% Newsbottom 21% Moat: Editorial + unicorn rating 7/10 · IP moat: 117 patents Funding: Raised $54.4M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $54M | 1 mo ago | 40 | Robert Giasolli Founder | Node.jsSalesforceRadix UI+26 | — | 117 patents Drug‑eluting serrated balloon catheters for precise intravascular drug delivery | 1 launch |
Top 12 Life Sciences companies in United States
#1
Verily 🦄Series D · Dallas, Texas · founded 2015 · 1564 employees$2.5Braised▾
Verily 🦄
Series D · Dallas, Texas · founded 2015 · 1564 employees
A data platform and technology company purpose-built to power AI-enabled precision health. The company combine deep clinical, regulatory, and technological expertise to provide customers with patient-centric solutions that make healthcare more personal and precise. The solutions are designed to make healthcare data AI-ready and fit for purpose across care, research, and public health.
Fliar Intelligence Index™ 84how this company ranks against its industry peers
News
top 13%Funding
top 14%Talent
top 22%Growth
top 25%Moat
top 26%Tech
top 30%News: 7 BI events in 12 mo (of 67 tracked, 9 types) · +600% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $2.5B across 5 rounds · 5 rounds over 9 yrs (0.6/yr) · Last round Series D (Mar 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 181k LinkedIn followers — 11.7% of this cohort's audience
Funding rounds
- Mar 2026Series D$300M
- Apr 2025Grant (prize money)$14.7M
- Sep 2022PE—
- Dec 2020PE$700M
Founders & team
Investors
Silver Lake, Ontario Teachers' Pension Plan, Temasek, Swiss Re, The Michael J. Fox Foundation, Series X Capital
Tech stack
Apple Icloud MailCore-JsDocusignEmotionGoogle AnalyticsGoogle Cloud
#2
Series E · Fremont, California · founded 2016 · 197 employees$680Mraised▾
Series E · Fremont, California · founded 2016 · 197 employees
Provider of implantable brain-computer interfaces. It offers flagship product the N1 Implant the Link which is a coin-sized device designed to decode neural signals and enable users to control digital devices using only their thoughts. It also has an experimental device called Blindsight to restore vision in individuals with optic nerve damage by directly stimulating the visual cortex.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Funding
top 15%Patents
top 25%Moat
top 25%Innovation
top 27%Talent
top 28%Market
top 33%Funding: Raised $680M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) · Last round Series E (May 2026)
Patents: 97 patents matched (strict assignee match) · 62 filings since 2022 vs 35 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 9/10 · IP moat: 97 patents · Unicorn
Audience (LinkedIn): 414k LinkedIn followers — 26.8% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2026Series E—
- May 2025Series E$650M
- Nov 2023Series D$43M
- Aug 2023Series D$323.2M
Founders & team
Investors
Founders Fund, Advaita Capital, Setcoin Group, MarketX, Ipo Club, Type One Ventures
Tech stack
Amazon AlbAmazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesApple Icloud Mail
#3
Public · San Francisco, California · founded 2012 · 21 employees$420.1Mraised▾
Public · San Francisco, California · founded 2012 · 21 employees
Developer of therapeutics for orthopedic diseases. It offers a lead candidate NOV004 which is an anabolic peptide engineered to target and concentrate at the bone fracture site and also helps in spinal fusion and osteogenesis Imperfecta.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 13%Growth
top 37%Tech
top 44%Moat
top 48%Talent
bottom 49%Market
bottom 37%Funding: Raised $420M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Post IPO (May 2026)
Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Tech: 37 technologies across 3/8 capability areas · Cloud: Amazon Web Services, Cloudflare · Security: Cloudflare Bot Management, Hsts
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. LifeSci Capital) announced in 12 mo
Funding rounds
- May 2026Post IPO$187M
- Feb 2020Post IPO$125M
- May 2018Series B$84.5M
- Feb 2017Series A$7.6M
Founders & team
Investors
Breakout Labs, Dolby Family Ventures, Takeda, Pfizer Venture Investments, Takeda Ventures, Sequoia Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#4
Series D · Middletown, Delaware · founded 2021$787Mraised▾
Series D · Middletown, Delaware · founded 2021
Provider of AI-driven technology platforms that enable the discovery and development of protein therapeutics. It transform the discovery of protein therapeutics using deep learning and high-throughput biology. The company aims to deliver transformative medicines to patients worldwide through its innovative approaches.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 12%AI
top 35%Talent
top 38%Patents
top 46%Innovation
top 50%Global
top 50%Funding: Raised $787M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series D (Mar 2026)
AI: Product described with: ai-driven, deep learning
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding rounds
- Mar 2026Series D$787M
Founders & team
Investors
Dimension, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi Ventures
#5
Series E · Campbell, California · founded 2015 · 90 employees$496Mraised▾
Series E · Campbell, California · founded 2015 · 90 employees
Provider of access catheters for cardiovascular diagnosis and treatment. The catheters are used in deep navigation into the blood vessels of the brain to prevent strokes. The flagship product ZOOM Aspiration System is a family of products designed to facilitate clot removal during ischemic stroke.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Funding
top 14%Patents
top 15%Innovation
top 18%Moat
top 26%Growth
top 27%Tech
top 36%Funding: Raised $496M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series E (Mar 2026)
Patents: 261 patents matched (strict assignee match) · 225 filings since 2022 vs 36 in 2017-21 · Latest publication 2026
Innovation: 261 patents (top 10% of patent-holders) · 225 filings since 2022 vs 36 in 2017-21
Audience (LinkedIn): 37k LinkedIn followers — 2.4% of this cohort's audience
Funding rounds
- Mar 2026Series E$100M
- Jul 2024Series E$150M
- Jul 2021Series D$260M
- Dec 2019Series C$86M
Founders & team
Investors
Delos Capital, HealthCor Partners, Ally Bridge Group, Rock Springs Capital, Ascension, Innovatus Capital Partners
Tech stack
Apple Icloud MailAutoptimizeCdnjsCloudflareCloudflare Bot ManagementContact Form 7
#6
Public · Menlo Park, California · founded 2016 · 491 employees$2Braised▾
Public · Menlo Park, California · founded 2016 · 491 employees
Developer of a screening platform for circulating tumor DNA to detect cancer. The company is developing a test called "Galleri" a pan-cancer screening test by measuring circulating nucleic acids in the blood. Its proprietary platform uses the ultra-deep sequencing technique to measure levels of circulating tumor DNA in the patient's blood.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Patents
top 13%Tech
top 16%News
top 17%Funding
top 20%Innovation
top 25%Growth
top 36%Patents: 899 patents matched (strict assignee match) · 523 filings since 2022 vs 371 in 2017-21 · Latest publication 2026
Tech: 51 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront · Devops: Nginx
News: 11 BI events in 12 mo (of 75 tracked, 14 types) · +83% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 113k LinkedIn followers — 7.3% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$325M
- Nov 2019Series D$390M
- May 2018Series C$300M
- Jun 2017Series B—
Founders & team
Investors
PSP Investments, CPP Investments, Illumina, Arch Venture Partners, Johnson & Johnson Innovation, McKesson Ventures
Tech stack
Amazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesApolloApple Icloud Mail
#7
Public · Seattle, Washington · founded 1991 · 25 employees$263.6Mraised▾
Public · Seattle, Washington · founded 1991 · 25 employees
Developer of plant-based alkaloid for treating smoking cessation. The company is developing Cytisinicline, which is a plant-based alkaloid with a binding affinity to the α4β2 nicotine receptor. The candidate is expected to block nicotine cravings and reduce the severity of nicotine withdrawal symptoms.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 11%News
top 42%Moat
top 48%Tech
top 50%Global
bottom 44%Market
bottom 40%Funding: Raised $264M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Post IPO (Apr 2026)
News: 9 BI events in 12 mo (of 54 tracked, 8 types) · -53% YoY · Top themes: Leadership, Earnings
Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Apr 2026Post IPO$180M
- Feb 2024Post IPO$60M
- Nov 2022Post IPO$18.9M
- Aug 2021Grant (prize money)$2.8M
Investors
Propel Bio Partners, Nantahala Capital Management, Sopharma Group, HHS, Frazier Life Sciences, TPG
Tech stack
Apache Http ServerBootstrapCdnjsCloudflareCloudflare Bot ManagementGoogle Tag Manager
#8
Public · New York City, New York · founded 2003 · 77 employees$559.7Mraised▾
Public · New York City, New York · founded 2003 · 77 employees
Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases. The product pipeline of the company includes vidofludimus calcium (IMU-838), a selective immune modulator for multiple sclerosis, IMU-935, a selective inverse agonist targeted for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome and IMU-856, for bowel barrier dysfunction.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 19%Tech
top 41%Moat
top 48%Growth
top 50%Talent
bottom 49%Global
bottom 45%Funding: Raised $560M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Post IPO (Feb 2026)
Tech: 34 technologies across 3/8 capability areas · Cloud: Cloudflare, Google Cloud · Security: Cloudflare Bot Management, Hsts
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- Feb 2026Post IPO$400M
- Jan 2024Post IPO$80M
- Oct 2022Post IPO$60M
- Sep 2016Post IPO$19.7M
Founders & team
Investors
BVF Partners, Janus Henderson Investors, Soleus Capital, RTW Investments, Adage Capital Management, Avidity Partners
Tech stack
Apache Http ServerBricksCloudflareCloudflare Bot ManagementCookiebotCore-Js
#9
Public · San Francisco, California · founded 2016 · 122 employees$158Mraised▾
Public · San Francisco, California · founded 2016 · 122 employees
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Funding
top 21%Talent
top 22%Tech
top 32%Innovation
top 34%News
bottom 43%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Post IPO (May 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- May 2026Post IPO$40M
- Dec 2024Post IPO$37.6M
- Dec 2024Post IPO$10M
- Jun 2024Grant (prize money)$8M
Founders & team
Investors
Matrix Partners China, Mirae Asset, Ridgeback Capital Management, Lux Capital, Gaingels, KB Investment
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAddthisAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#10
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees$207.8Mraised▾
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees
Developer of small molecule-based therapeutics for the treatment of obstructive sleep apnea. The company has developed a combination of Atomoxetine and Oxybutynin which reduces the obstructive sleep apnea severity. It targets the neurological control and activation of upper airway dilator muscles which improve respiration and oxygenation during sleep.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 14%Growth
top 28%Talent
top 28%Moat
top 35%Product
top 40%Tech
bottom 49%Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Conventional Debt (Apr 2026)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Talent: Analyst team rating 5/5 · 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 22k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Regional Director, Field Medical Affairs
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Conventional Debt$50M
- Mar 2026Series C$25M
- Sep 2025Conventional Debt$35M
- Apr 2025Series C$16.5M
Founders & team
Investors
Tao Capital Partners, Morningside, Alpha Wave Global, Sectoral, Columbia-Seligman Investments, NexPoint
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsDocusign
#11
Series E · San Ramon, California · founded 2003 · 20 employees$181.4Mraised▾
Series E · San Ramon, California · founded 2003 · 20 employees
BioVentrix develops clinical solutions for treating heart failure patients. It provides PliCath HF, an epicardial catheter-based ventricular reconstruction device. Product is not commercially available.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 16%Moat
top 19%Patents
top 36%Talent
top 38%Innovation
top 43%Global
bottom 45%Funding: Raised $181M across 25 rounds · 25 rounds over 22 yrs (1.1/yr) · Last round Series E (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 185 patents · Soonicorn
Patents: 185 patents matched (strict assignee match) · 29 filings since 2022 vs 71 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. BioVentrix, Inc.) announced in 12 mo
Funding rounds
- Apr 2026Series E$705K
- Oct 2024Series E$6.7M
- Mar 2024Series E$3.6M
- Apr 2023Series E$48.5M
Founders & team
Investors
Taglich Brothers, Andera Partners, Cormorant Asset Management, Squarepoint Capital, Richmond Brothers, Telegraph Hill Partners
Tech stack
BootstrapCloudwaysGoogle AnalyticsGsapIsotopeJquery
#12
Series C · San Francisco, California · founded 2021 · 35 employees$250Mraised▾
Series C · San Francisco, California · founded 2021 · 35 employees
Developer of small-molecule therapeutics for cancer treatment. It provides a lysine-targeted covalency platform to develop therapies against known drug targets for oncology.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%Talent
top 28%Moat
top 31%Growth
top 35%Tech
top 49%Market
bottom 41%Funding: Raised $250M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series C (Apr 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Apr 2026Series C$108M
- Nov 2023Series B$175M
- May 2022Series A$75M
Founders & team
Investors
Orbimed, Third Rock Ventures, EcoR1, Novo Holdings, Cormorant Capital, RA Capital Management
Tech stack
All In One SeoAmazon Web ServicesApple Icloud MailBugherdCdnjsCloudflare
Funding & investor landscape
$396.2Btotal disclosed funding
9,512companies funded
37,280disclosed rounds
121rounds last 90 days
Most active investors
Notable founders
Andrew Conrad
Co-Founder · Verily
Jessica Mega
Co-Founder · Verily
Dongjin Seo
Co-Founder · Neuralink
Elon Musk
Co-Foudner & CEO & Owner · Neuralink
Dirk Thye
CEO · Quince Therapeutics
Zhenping Zhu
Co-Founder & Co-CEO · Earendil
Jian Peng
Founder & Co-CEO · Earendil
Dr Hopkins
Co-founder · Imperative Care
Fred Khosravi
Co-Founder & CEO · Imperative Care
Bob Ragusa
Chief Executive Officer · GRAIL
Daniel Vitt
Chief Executive Officer · Immunic
Jim Collins
Co-Founder · Senti Bio
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research is surging — papers rose from 33 to 164, even as breakthroughs' overall field-share fell from 41% to 30%.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and fermentation advancements are intensifying simultaneously — papers jumped from 3→62 and 2→54 respectively.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern research is rising sharply — papers tripled from 15 to 45 across U.S. biotechnology institutions.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18113
- UNIV California17975
- Regeneron Pharma16083
- Amgen10515
- Monsanto Technology9755
- UNIV Pennsylvania8528
- Harvard College7464
- UNIV Texas7384
Common questions
How many Life Sciences companies are there in United States?
Radar tracks 19639 indexable Life Sciences companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in United States?
The Life Sciences companies in United States on this list have raised a combined $396.2B in disclosed equity funding across 9512 funded companies.
Which is the highest-funded Life Sciences company in United States?
Moderna is the highest-funded Life Sciences company in United States, with $2.8B in disclosed equity funding.
How many Life Sciences companies in United States are funded?
9512 of the 19639 Life Sciences companies in United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in United States?
47 Life Sciences companies in United States on this list are valued at $1B or more.
Who are the top investors in United States Life Sciences companies?
The most active investors in United States Life Sciences companies on this list include HHS, National Science Foundation, NIH, Orbimed, RA Capital Management.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.